SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass., September 08, 2025--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of ...
TOKYO, Sept. 3, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will deliver a total of 11 presentations, including clinical data ...
Brendon Yee, PhD, professor and respiratory and sleep physician, Woolcock Institute of Medical Research, discusses the success of ALKS 2680, an investigational oral selective orexin 2 receptor agonist ...
Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological, ...
An investigational oral selective orexin receptor 2 agonist (oveporexton, Takeda) demonstrated significantly improved measures of wakefulness, sleepiness, and cataplexy in a phase 2b study of adults ...
ZURICH, SWITZERLAND / ACCESSWIRE / June 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering ...
Please provide your email address to receive an email when new articles are posted on . Idorsia Pharmaceuticals announced that a citizen petition was filed on its behalf, asking the DEA to de-schedule ...
Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback